WALA UK LIMITED

1. Risk Rating: MEDIUM

Justification: The company is presently solvent, liquid, and up to date with its statutory filings. However, the restoration of positive shareholders’ funds in 2025 is entirely attributable to a one-off debt waiver from its parent company rather than underlying trading performance, and the business has a multi-year history of negative equity and dependence on related-party funding before that event.

2. Key Concerns

• Non-recurring nature of the 2025 improvement: The reported profit of £3,346,361 for the year ended 31 December 2025 includes an exceptional item of £3,284,044 representing debt forgiven by WALA Heilmittel GmbH for deliveries and services from 2021 to 2024. Excluding this item, the company would remain deeply loss-making and balance sheet insolvent.
• Prolonged historical balance sheet weakness: Shareholders’ funds were negative in every year from 2019 through 2024, reaching a low of £-2,568,560 at 31 December 2024. This indicates chronic undercapitalisation and sustained reliance on related-party support.
• Related-party dependency and recent board change: Amounts owed to group undertakings fell from £3,497,828 in 2024 to £72,049 in 2025 following the debt waiver. A director resigned on 31 January 2026, leaving two current directors; the reason for the resignation is not disclosed in the available data.

3. Positive Indicators

• Current solvency: Shareholders’ funds are £827,801 and net current assets are £809,312, with current assets of £1,189,082 against current liabilities of £379,770.
• Adequate short-term liquidity: Cash at bank and in hand was £502,440 at year-end, sufficient to cover current liabilities.
• Regulatory compliance: Annual accounts and confirmation statement are not overdue; the audit opinion on the statutory financial statements is unqualified.
• Stable workforce: The average number of employees was 21 in both 2024 and 2025.

4. Due Diligence Notes

• The filed accounts omit the profit and loss account; request the full statutory financial statements to isolate underlying trading results from the exceptional debt waiver.
• Establish whether any further amounts owed to group undertakings remain outstanding or could be reinstated, and whether the parent has provided any formal commitment to ongoing financial support.
• Review 2026 trading forecasts and working capital requirements to determine whether the company can operate independently of further parent funding.
• Investigate the circumstances surrounding the director’s resignation on 31 January 2026 and any resulting changes to board oversight or decision-making.
• Examine the recoverability and ageing of debtors (£349,951) and the nature and valuation of stock (£336,691).
• Identify any contingent liabilities, legal claims, or onerous contractual commitments not apparent from the balance sheet.